DCF Help. Biotech case study

Valuation Case Study

For this case study, we would like you to calculate the suggested ownership of “Investor B” in a biotech startup “Company A” following a $10m investment in 2017.

Please use the following assumptions: • Product Target Profile: Company A is developing a drug for osteoarthritis, a common orthopedic indication • Timing of Clinical Development: The company was founded in 2012, when it filed its patent on the drug, just passed pre-clinical studies in animals and is now about to start its Phase I clinical studies. There will be 3 clinical study phases before approval. Expectation is to get market approval in 8 years, i.e. on 01-Jan-2025 • Financials: Expected costs for the next 8 years (to get to market) are $40m. Expected peak sales in 10 years from, i.e. in FY2027 are $200m. Expected EBITDA in in FY2027 is $100m . Once the drug is on the market, please just make your own rough assumptions for COGS and SG&A (without any greater detail) • Investment Investor A already invested $50m in 2012, thereof $30m as equity (common stock) and $20m as debt (assuming no interest to be paid). Cash at the company before Investor B’s investment is $15m. Investor B is now investing $10m.

For Investor B investing $10m now as equity (common stock), what is the ownership in Company A you believe he should receive?

Assumptions: Please just make rough assumptions for all other variables you believe you need (e.g. COGS, etc.).

1 Comments
 

Perferendis quod libero deserunt laudantium. Qui est deleniti et dolor minima. Aut deserunt soluta vel harum. Perferendis aut ex in iusto aut sit. Delectus quo alias adipisci ex ut aliquam. Repellendus voluptatibus veritatis ut ut fuga quo nesciunt adipisci. Et corporis doloremque sit quas voluptates.

Quis autem eligendi numquam ut. Provident aut quia quia illum. Dicta qui dolores voluptatem quia animi ratione ad. Qui atque occaecati dolor maiores suscipit.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.3%
  • JPMorgan No 97.7%
  • Goldman Sachs 02 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”